lundi 10 octobre 2016

Onco Actu du 10 octobre 2016 - Spécial ESMO

5.6 ESMO

Financial Difficulties Linked to Worse Outcomes From Cancer Treatment [ESMO]

First Feasibility Study of the ESMO-MCBS Scale in Rare Tumour Entities [ESMO]

5.6.1 ESMO - Essais

Single-Arm Trials Improve Early Access to Rare Cancer Drugs [ESMO]

5.6.10 ESMO - Vessie

Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer [BMS]

New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients [Merck]

Immunotherapy Shows Promising Results in First and Second Line Treatment of Metastatic Bladder Cancer [ESMO]

Merck's Keytruda achieves 24 percent response in bladder cancer study [Reuters]

5.6.11 ESMO- Rein

Updated Results Presented for the Opdivo (nivolumab) and Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma From Phase 1 Study [BMS]

Longer Disease-free Survival in Phase III Trial of Sunitinib as Adjuvant Treatment for Kidney Cancer [ESMO]

Cabozantinib Improves Progression-free Survival in Metastatic Renal Cell Carcinoma [ESMO]

5.6.12 ESMO - Observation

Factors Identified That Associate with Near the End of Life Chemotherapy Use [ESMO]

True Burden of Head and Neck Cancer in France Underestimated by More Than One-Third [ESMO]

Women diagnosed with breast cancer after 70 twice as likely to die from it [The Telegraph]

Thousands of European melanoma patients lack access to new drugs [Reuters]

5.6.13 ESMO - Prostate

Custirsen Shows no Survival Benefits in Metastatic Prostate Cancer [ESMO]

Dietary saturated fat linked to aggressive prostate cancer [Reuters]

5.6.14 ESMO - Ovaire

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition [The Street]

Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial [ESMO]

The race to create a new class of ovarian cancer drugs heats up [STAT]

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows [The Street]

Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress [Clovis]

Tesaro makes its case for a clean sweep with niraparib, voiding need for a diagnostic [EndPoints]

Clovis shares tank after investors size up the disappointing data on rucaparib [EndPoints]

Tesaro ovarian cancer drug shows broad benefits in study [Reuters]

5.6.15 ESMO - VADS

Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study [BMS]

Nivolumab Maintains Function and Reduces Symptoms in Relapsed Metastatic Head and Neck Cancer [ESMO]

Immunotherapy cancer drug hailed as 'game changer' [BBC News]

Immunotherapy drug a 'gamechanger' for head and neck cancer [The Guardian]

5.6.2 ESMO - Divers

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors [Exelixis]

Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress [BMS]

Significant Survival Gains from Neoadjuvant Chemotherapy for High-risk Soft Tissue Sarcoma [ESMO]

Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours [ESMO]

Trabectedin Improves PFS Over Best Supportive Care in Patients with Pretreated Advanced Soft Tissue Sarcoma [ESMO]

5.6.4 ESMO - Poumon

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress [Merck]

Two Major Studies to Be Presented at ESMO 2016 Congress Presidential Symposium Demonstrate Potential of Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in a Broad Range of Patients [Merck]

Roche’s TECENTRIQ (atezolizumab) shows significant survival advantage compared to chemotherapy regardless of PD-L1 status in a specific type of lung cancer in Phase III study [Roche]

MEK Inhibition in KRAS-mutant NSCLC Did Not Improve Survival [ESMO]

Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study [Novartis]

Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer [BMS]

Still no Opdivo benefit in subgroup breakdown of Bristol's first-line NSCLC flop [FiercePharma]

Overall survival data from LUX-Lung 7 head-to-head trial of afatinib versus gefitinib presented at ESMO 2016 [Boehringer Ingelheim]

New Data on the Combination of Lilly's ALIMTA® (pemetrexed) and Merck's KEYTRUDA® (pembrolizumab) Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic Non-Small Cell Lung Cancer [Lilly]

Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer [BMS]

Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung [ESMO]

Pembrolizumab New Option for First Line Treatment of Patients with Advanced Lung Cancer and High PD-L1 Expression [ESMO]

Bristol's Opdivo Disappoints in Lung Cancer, Losing Ground To Rival Merck [Forbes]

Merck’s glorious victory in lung cancer marks a Russian winter for Bristol-Myers [EndPoints]

Ceritinib Provides Longer Progression-free Survival Than Chemotherapy in Phase III Trial of ALK Rearranged Lung Cancer Treatment [ESMO]

Merck Solidifies Lung Cancer Immunotherapy Lead over Bristol-Myers Squibb [The Street]

Greater Patient Selection May be Needed for First Line Nivolumab to Improve Progression-free Survival in Advanced Lung Cancer [ESMO]

First-line Pembrolizumab Plus Chemotherapy Significantly Improves Outcomes in Advanced NSCLC [ESMO]

Significant Survival Gains with Atezolizumab vs Docetaxel for Non-Small-Cell Lung Cancer [ESMO]

Merck drug shines in lung cancer and also works with chemo [Reuters]

No silver lining in failed Bristol cancer drug trial [Reuters]

Roche lung cancer drug success adds to pressure on Bristol [Reuters]

Bristol drug flop opens big cancer opportunity: AstraZeneca CEO [Reuters]

5.6.5 ESMO - Mélanome & Peau

Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study [BMS]

Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up [Novartis]

Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress [Merck]

Ipilimumab as Adjuvant Therapy Improves Overall Survival in High Risk Stage III Melanoma [ESMO]

5.6.6 ESMO - Sein

Antitumour Activity Demonstrated With Lurbinectedin in Patients With Metastatic Breast Cancer and BRCA Mutations [ESMO]

Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care [Novartis]

Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress [Clovis]

Targeting Estrogen Receptor Improves Progression-free Survival in Advanced Breast Cancer [ESMO]

Ribociclib Improves Progression-free Survival in Advanced Breast Cancer [ESMO]

Novartis heads to the finish line with CDK 4/6 blockbuster contender ribociclib [EndPoints]

Encouraging Results For Ribociclib In Advanced Breast Cancer [Forbes]

Novartis challenges Pfizer with strong breast cancer drug data [Reuters]

5.6.8 ESMO - Côlon-rectum

ERBB2 Gene Alterations May Be Prognostic of Poorer Outcome in Stage III Colon Cancer [ESMO]

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016 [Boehringer Ingelheim]

Results of the First Cohort of Patients Screened Within the New EORTC Molecular Platform for Patients With Colorectal Cancer [ESMO]

Triple Combination of Dabrafenib, Trametinib, and Panitumumab Improves Efficacy in BRAF Mutation Positive mCRC [ESMO]

Comprehensive Genomic Profiling Identifies Potentially Actionable Mutations in Small Bowel Adenocarcinoma [ESMO]

A Longer Interval Between Preoperative Chemoradiotherapy and Surgery Urged in Locally Advanced Rectal Cancer [ESMO]

Nintedanib Improves Progression-free Survival but not Overall Survival in Phase III Trial of Metastatic Colorectal Cancer [ESMO]